Central Nervous System

Remepy secures $36m funding for hybrid drug pipeline expansion

Remepy has closed a $36m Series A financing round to accelerate its pharmaceutical co-development partnerships and expand its hybrid drug pipeline.

Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront

Jazz Pharmaceuticals has signed a definitive agreement to purchase Actio Biosciences in a deal that includes an upfront payment of $820m and up to $500m in additional contingent payments.

Kenvue’s Tylenol with Naproxen gains FDA approval

The US Food and Drug Administration (FDA) has approved Kenvue’s Tylenol with Naproxen, the first over-the-counter (OTC) fixed-dose combination of acetaminophen (650mg) and naproxen sodium (220mg).

FDA grants fast track designation for Lundbeck’s Lu AH69593

Lundbeck has secured fast track designation from the US Food and Drug Administration (FDA) for its investigational treatment, Lu AH69593, to treat narcolepsy.

Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar

Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).

FDA approves Eisai and Biogen’s Leqembi Iqlik BLA for early Alzheimer’s

The US Food and Drug Administration (FDA) has granted approval for Eisai and Biogen’s biologics licence application (BLA) for Leqembi Iqlik, a once-weekly subcutaneous injection maintenance dosing to treat early Alzheimer's disease (AD).

Secarna, Vect-Horus partner to develop RNA-targeted therapeutics

Secarna Pharmaceuticals and Vect-Horus have entered a research collaboration for developing RNA-targeted therapeutics capable of crossing the blood-brain barrier (BBB) for treating central nervous system (CNS) diseases.

EC grants orphan drug status to JR-446 for MPS IIIB

The European Commission (EC) has granted orphan drug designation (ODD) to Medipal and JCR Pharmaceuticals' investigational drug, JR-446, to treat mucopolysaccharidosis type IIIB (MPS IIIB), also known as Sanfilippo syndrome type B.

GRIN Therapeutics and Angelini Pharma collaborate on radiprodil development

GRIN Therapeutics has announced a collaboration with Angelini Pharma to develop and commercialise radiprodil outside of North America.